THE UNIVERSITY OF KENTUCKY joined the TriNetX network for its clinical trial design and clinical research. Pharmaceutical researchers will gain access to the university’s clinical data through TriNetX’s network of healthcare institutions representing over 37 million patients in the U.S. and Europe to support clinical study and protocol design, site selection, and patient recruitment across...
The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.
